{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:23:54Z","timestamp":1747185834886,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most patients with hypertension are complicated with insulin resistance (IR), which is one of the risk factors of hypertension and can increase the level of serum homocysteine (Hcy) by affecting Hcy's metabolic enzyme and insulin level. Investigations in recent years have shown that Hcy is an independent risk factor for cardiovascular diseases. At present, folic acid is the prominent medicine used to reduce Hcy, but its effection for Hcy has an obvious individual difference, which is closely related to individual genes. Moreover, folic acid is chiefly used in patients with Hcy \u226515\u00a0\u03bcmol\/L, but Hcy \u226510\u00a0\u03bcmol\/L has had an adverse effect on the cardiovascular system. Randomized clinical trials have shown that dapagliflozin can improve IR. Therefore, whether it can reduce Hcy has become a new direction. This study was a retrospective case\u2013control study. Patients with high serum Hcy and hypertension complicated with IR were divided into two groups: the dapagliflozin group (<jats:italic>n<\/jats:italic>\u00a0=\u00a0166) and the control group (<jats:italic>n<\/jats:italic>\u00a0=\u00a0198). Before and after 12\u00a0weeks of treatment, the changes in serum Hcy and IR index were measured and compared. We found that dapagliflozin could reduce the serum Hcy level of patients with hypertension and IR to a certain extent. Dapagliflozin could be a viable option for hypertension complicated with IR and hyperhomocysteinemia. However, these findings need to be further confirmed in future randomized clinical trials with a large number of samples.<\/jats:p>","DOI":"10.1111\/jch.14662","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T11:34:19Z","timestamp":1683027259000},"page":"489-496","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance"],"prefix":"10.1111","volume":"25","author":[{"given":"Xiaoqian","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Cardiology Jinan Central Hospital, Shandong University  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Cardiology Jinan Central Hospital Weifang Medical University  Weifang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-2451","authenticated-orcid":false,"given":"Rui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology Jinan Central Hospital, Shandong University  Jinan China"},{"name":"Department of Cardiology Jinan Central Hospital Weifang Medical University  Weifang China"},{"name":"Department of Cardiology Central Hospital Affiliated to Shandong First Medical University  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound Shandong Provincial Qianfoshan Hospital Shandong University  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032380"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834e4aaa"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.11.009"},{"key":"e_1_2_11_5_1","article-title":"Homocysteine\u2010lowering interventions for preventing cardiovascular events","volume":"8","author":"Mart\u00ed\u2010Carvajal AJ","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109821"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2006.03.010"},{"issue":"09","key":"e_1_2_11_8_1","first-page":"1685","article-title":"Research progress on the relationship between homocysteine and hypertension","volume":"37","author":"Xu H","year":"2022","journal-title":"Guangming J Chin Med"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-19125-9"},{"issue":"03","key":"e_1_2_11_10_1","first-page":"152","article-title":"Research Progress in Hyperhomocysteine and H type Hypertension","volume":"4","author":"Chen K","year":"2020","journal-title":"Moderen Med Health Res"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180313105949"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-019-0672-7"},{"issue":"06","key":"e_1_2_11_13_1","first-page":"1","article-title":"The expert consensus on the diagnosis, treatment, and prevention of hyperhomocysteinemia","volume":"29","author":"Li D","year":"2022","journal-title":"J Rare Uncommon Diseases"},{"issue":"05","key":"e_1_2_11_14_1","first-page":"23","article-title":"Expert consensus on the diagnosis and treatment of H\u2010type hypertension","volume":"8","author":"Li J","year":"2016","journal-title":"Chin J Hypertens"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-19-0385"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.09.006"},{"issue":"8","key":"e_1_2_11_17_1","first-page":"5622","article-title":"The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy","volume":"14","author":"Li Q","year":"2022","journal-title":"Am J Transl Res"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.5603\/KP.2019.0018"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.08.029"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030393"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01474-z"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162965"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0297-x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0167"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30316"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114009"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.14662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T03:59:41Z","timestamp":1697860781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.14662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/jch.14662"],"URL":"https:\/\/doi.org\/10.1111\/jch.14662","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"type":"print","value":"1524-6175"},{"type":"electronic","value":"1751-7176"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2023-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}